← Eichor
Study identifier: NCT07127172 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

Condition: Tetraplegia/Tetraparesis · Quadriplegia · Quadriplegia/Tetraplegia  ·  Sponsor: Neuralink Corp

PhaseNA
Planned participants7
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions. The N1 Implant is a wireless, rechargeable device mounted on the skull, connected to electrode threads that are inserted into the brain by the R1 Robot, which is a robotic device specifically designed for this procedure.

This description comes directly from the study's public registry record.

Talk to the study team

Neuralink Clinical Team  ·  (877) 398-4465  ·  clinical-team-ct@neuralink.com

Always discuss trial participation with your own doctor first.

Locations (2)

University College London Hospitals NHS Foundation TrustLondon, Greater London, United KingdomRecruiting
The Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, Tyne and Wear, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07127172